New Results for GIVLAARI® (givosiran) at the American College of Gastroenterology 2020 Virtual Annual Scientific Meeting

New Results for GIVLAARI® (givosiran) at the American College of Gastroenterology 2020 Virtual Annual Scientific Meeting

New data from a post-hoc analysis of the ENVISION Phase 3 study of GIVLAARI® (givosiran) were presented during the American College of Gastroenterology 2020 Virtual Annual Scientific Meeting, evaluating outcomes in patients with acute hepatic porphyria with or without prior hemin prophylaxis. Findings on healthcare resource utilization among patients with acute intermittent porphyria were also presented, along with encore 12-month interim data from the open-label extension period of the ENVISION Phase 3 study.

Bonkovsky, et al. “Clinical Outcomes in Patients with Acute Hepatic Porphyria Treated with Givosiran Who Stopped Hemin Prophylaxis at Study Entry: A Post-hoc Analysis of Data From the Phase 3 ENVISION Study Through Month 12”

Silver, et al. “Disease Burden and Healthcare Utilization Among Patients with Acute Intermittent Porphyria Experiencing Chronic Pain: Analyses from a National Healthcare Database”

Sardh, et al. “Twelve-Month Interim Analysis of Efficacy and Safety of Givosiran, an Investigational RNAi Therapeutic for Acute Hepatic Porphyria, in the ENVISION Open-Label Extension”



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.